Potential Link Between a Treatment for Systemic Juvenile Idiopathic Arthritis and Lung Disease

The number of systemic juvenile idiopathic arthritis patients who develop lung disease (sJIA-LD) is rising in both the U.S., Europe, the Middle East, and Canada. This trend has been notable…

Continue Reading Potential Link Between a Treatment for Systemic Juvenile Idiopathic Arthritis and Lung Disease

Study Shows Tysabri Reduces Risk of Cognitive Decline for Pediatric-Onset Multiple Sclerosis Patients

The Gap Tysabri is a therapy that has shown efficacy for reducing disease activity in patients diagnosed with pediatric-onset multiple sclerosis (POMS). Previous investigations have indicated that up to 58%…

Continue Reading Study Shows Tysabri Reduces Risk of Cognitive Decline for Pediatric-Onset Multiple Sclerosis Patients
Phase 3 Clinical Trial for Amyotrophic Lateral Sclerosis Has Completed Enrollment
source: pixabay.com

Phase 3 Clinical Trial for Amyotrophic Lateral Sclerosis Has Completed Enrollment

BrainStorm Cell Therapeutics has just announced that they have completed enrollment in their Phase 3 clinical trial for amyotrophic lateral sclerosis (ALS). Enrollment was initiated way back in October of…

Continue Reading Phase 3 Clinical Trial for Amyotrophic Lateral Sclerosis Has Completed Enrollment

The FDA Has Just Approved the Very First Therapy for Erythropoietic Protoporphyria

EPP Erythropoietic protoporphyria (EPP) is a rare disease that causes extreme light sensitivity. This sensitivity is so extreme that being outside is extremely difficult for patients and many only come…

Continue Reading The FDA Has Just Approved the Very First Therapy for Erythropoietic Protoporphyria

Interactive Patient Registry Created by NHF Allows Hemophilia Patients to be More Involved in Their Healthcare

A New Collaboration The National Hemophilia Foundation (NHF) is a nonprofit specifically focused on accelerating research for Hemophilia, a rare blood disorder. It was established in 1948 and now has…

Continue Reading Interactive Patient Registry Created by NHF Allows Hemophilia Patients to be More Involved in Their Healthcare

Experimental Treatment for Facioscapulohumeral Muscular Dystrophy has Disappointing Results but May Still Benefit Charcot-Marie-Tooth Disease

The Bad News Unfortunately, it has recently been announced that an experimental treatment for facioscapulohumeral muscular dystrophy (FSHD) will not be continuing on in clinical trials. This is because the…

Continue Reading Experimental Treatment for Facioscapulohumeral Muscular Dystrophy has Disappointing Results but May Still Benefit Charcot-Marie-Tooth Disease

In Honor of Tay-Sachs Disease Awareness Month Organizations are Teaming Together to Spread Awareness of Genetic Testing

Tay-Sachs Disease September is Tay-Sachs Disease Awareness Month. Voted on by the Senate unanimously in 2008, this month aims to spread awareness about this disease and the importance of carrier…

Continue Reading In Honor of Tay-Sachs Disease Awareness Month Organizations are Teaming Together to Spread Awareness of Genetic Testing

The Power of Collective Action in Providing Insurance Coverage for Spinal Muscular Atrophy Gene Therapy

Maisie Green Maisie Green is a 20-month-old little girl whose insurance has finally approved coverage for a life-altering spinal muscular atrophy treatment. Two weeks ago she received the singular infusion…

Continue Reading The Power of Collective Action in Providing Insurance Coverage for Spinal Muscular Atrophy Gene Therapy